Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TTJSQEF)

Molecular Interaction Atlas (MIA) of This DTT

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This DTT

1 Approved Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Baricitinib	DM4ONW5	Rheumatoid arthritis	FA20	Approved	[1]
------------------------------------------------------------------------------------

7 Clinical Trial Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Asp-015K	DMZ1UOI	Psoriasis vulgaris	EA90	Phase 3	[2]
Masitinib	DMRSNEU	Amyotrophic lateral sclerosis	8B60.0	Phase 3	[3]
PF-04965842	DM8J29L	Atopic dermatitis	EA80	Phase 3	[4]
ATI-502	DMK3VYU	Atopic dermatitis	EA80	Phase 2	[4]
KD019	DMEFW3G	Brain metastases	2D50	Phase 2	[3], [5]
LEO 124249	DM7W0JE	Asthma	CA23	Phase 2	[4]
TD-1473	DMJG7AY	Ulcerative colitis	DD71	Phase 1	[2]
------------------------------------------------------------------------------------


⏷ Show the Full List of 7 Clinical Trial Drug(s)

8 Patented Agent(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Aminotriazolopyridine derivative 1	DMW2LZ0	N. A.	N. A.	Patented	[6]
Imidazo[4,5-c]pyridine derivative 1	DM4KBZQ	N. A.	N. A.	Patented	[6]
Imidazo[4,5-c]pyridine derivative 2	DMFDRJT	N. A.	N. A.	Patented	[6]
PMID27774822-Compound-Figure10CompoundA	DM3M6SE	N. A.	N. A.	Patented	[7]
PMID27774822-Compound-Figure10Example1	DMCTXPQ	N. A.	N. A.	Patented	[7]
PMID27774824-Compound-Figure11Example1up	DMH1W8F	N. A.	N. A.	Patented	[6]
Ruxolitinib derivative 1	DM41ZW9	N. A.	N. A.	Patented	[6]
Tetra-cyclic compound 1	DMS1GJD	N. A.	N. A.	Patented	[6]
------------------------------------------------------------------------------------


⏷ Show the Full List of 8 Patented Agent(s)

4 Discontinued Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
SDZ-LAP-977	DMX4938	Psoriasis vulgaris	EA90	Discontinued in Phase 2	[8]
PN-355	DMFKC7L	Human immunodeficiency virus-1 infection	1C62	Discontinued in Phase 1	[9]
AP-23588	DMXLJBA	Osteoporosis	FB83.0	Terminated	[10]
CLX-0301	DMVUL4P	Diabetic complication	5A2Y	Terminated	[11]
------------------------------------------------------------------------------------

References

1	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
7	Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161.
8	Structure-activity relationship studies on a novel class of antiproliferative agents derived from Lavendustin A. Part I: Ring A modifications. Bioorg Med Chem. 2008 Aug 15;16(16):7552-60.
9	WO patent application no. 2005,0502,03, Biological materials and uses thereof.
10	Foye's Principles of Medicinal Chemistry, Thomas L. Lemke, David A. Williams. 2008. Page(950).
11	CLX-0901 (Calyx Therapeutics). Curr Opin Investig Drugs. 2001 May;2(5):650-3.